Retinitis Pigmentosa Clinical Trials 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Natural History of the Progression of X-Linked Retinitis Pigmentosa
Condition: X-Linked Retinitis Pigmentosa Intervention: Other: Other: Assessments Sponsor: NightstaRx Ltd, a Biogen Company Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 14, 2021 Category: Research Source Type: clinical trials
Pilot Study of Intravitreal Autologous CD34+ Stem Cell Therapy for Retinitis Pigmentosa
Condition: Retinitis Pigmentosa Intervention: Biological: Intravitreal autologous CD34+ cells Sponsors: University of California, Davis; Cures Within Reach Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 14, 2021 Category: Research Source Type: clinical trials
Natural History of the Progression of X-Linked Retinitis Pigmentosa
Condition: X-Linked Retinitis Pigmentosa Intervention: Other: Other: Assessments Sponsor: NightstaRx Ltd, a Biogen Company Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 14, 2021 Category: Research Source Type: clinical trials
Pilot Study of Intravitreal Autologous CD34+ Stem Cell Therapy for Retinitis Pigmentosa
Condition: Retinitis Pigmentosa Intervention: Biological: Intravitreal autologous CD34+ cells Sponsors: University of California, Davis; Cures Within Reach Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 14, 2021 Category: Research Source Type: clinical trials
Natural History of the Progression of X-Linked Retinitis Pigmentosa
Condition: X-Linked Retinitis Pigmentosa Intervention: Other: Other: Assessments Sponsor: NightstaRx Ltd, a Biogen Company Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 14, 2021 Category: Research Source Type: clinical trials
Pilot Study of Intravitreal Autologous CD34+ Stem Cell Therapy for Retinitis Pigmentosa
Condition: Retinitis Pigmentosa Intervention: Biological: Intravitreal autologous CD34+ cells Sponsors: University of California, Davis; Cures Within Reach Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 14, 2021 Category: Research Source Type: clinical trials
Natural History of the Progression of X-Linked Retinitis Pigmentosa
Condition: X-Linked Retinitis Pigmentosa Intervention: Other: Other: Assessments Sponsor: NightstaRx Ltd, a Biogen Company Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 14, 2021 Category: Research Source Type: clinical trials
Pilot Study of Intravitreal Autologous CD34+ Stem Cell Therapy for Retinitis Pigmentosa
Condition: Retinitis Pigmentosa Intervention: Biological: Intravitreal autologous CD34+ cells Sponsors: University of California, Davis; Cures Within Reach Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 14, 2021 Category: Research Source Type: clinical trials
Natural History of the Progression of X-Linked Retinitis Pigmentosa
Condition: X-Linked Retinitis Pigmentosa Intervention: Other: Other: Assessments Sponsor: NightstaRx Ltd, a Biogen Company Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 14, 2021 Category: Research Source Type: clinical trials
Pilot Study of Intravitreal Autologous CD34+ Stem Cell Therapy for Retinitis Pigmentosa
Condition: Retinitis Pigmentosa Intervention: Biological: Intravitreal autologous CD34+ cells Sponsors: University of California, Davis; Cures Within Reach Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 14, 2021 Category: Research Source Type: clinical trials
Natural History of the Progression of X-Linked Retinitis Pigmentosa
Condition: X-Linked Retinitis Pigmentosa Intervention: Other: Other: Assessments Sponsor: NightstaRx Ltd, a Biogen Company Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 14, 2021 Category: Research Source Type: clinical trials
Dose-Escalation Study to Evaluate the Safety and Tolerability of Intravitreal vMCO-I in Patients With Advanced Retinitis Pigmentosa
Conditions: Retinitis Pigmentosa; Retinal Diseases; Retinal Degeneration Intervention: Biological: Gene Therapy product:vMCO-I Sponsor: Nanoscope Therapeutics Inc. Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 9, 2021 Category: Research Source Type: clinical trials
